MS010

MS010 is a preclinical monoclonal antibody developed by Medimscience that targets MT010, a proprietary macrophage-related biological target. The drug is designed to modulate macrophage activity within the disease microenvironment, offering a potential therapeutic approach for both oncology and autoimmune conditions. Current development efforts are focused on solid tumors, inflammatory bowel disease (IBD), and psoriasis. As a macrophage-targeting agent, MS010 aims to either deplete tumor-associated macrophages or reprogram them to enhance anti-tumor immunity or reduce pathological inflammation.

Other names

MT010 antibodyMT-010 antibodyMT 010 antibody